Cephalon board rejects full Valeant bid: Valeant withdraws non-oncology bid
This article was originally published in Scrip
Executive Summary
Cephalon has rejected the unsolicited $5.7 billion acquisition bid by Valeant Pharmaceuticals. The US specialty pharma said the $73-a-share bid was "inadequate and not in the best interests of shareholders".